Pfenex to Regain Full Rights to PF582
News Aug 09, 2016
"With Pfenex regaining the rights to PF582 we are announcing the PF582 phase 1/2 safety and efficacy data which we believe highlights the significant value of the program," stated Bertrand C. Liang, chief executive officer of Pfenex. "We will consider strategic options for PF582 following the expeditious transition of the full development program back to Pfenex. Pfenex's development capabilities, leveraging our Pfenex Expression Technology® platform, has allowed us to advance a diverse portfolio of product candidates, including PF582, which we believe will create significant value for our shareholders. We look forward to providing key updates on our pipeline progress throughout the year."
Phase 1/2 PF582 Results
Pfenex enrolled a total of 25 VEGF-inhibitor naïve patients with neovascular age-related macular degeneration (AMD) in the PF582 phase 1/2 trial (13 received PF582, including 1 sentinel patient who received open label PF582, 12 received Lucentis). All patients received 3 monthly intravitreal injections. The primary endpoint of the study was safety and tolerability of PF582 compared to that of Lucentis in patients with neovascular AMD.
With respect to safety, there were no meaningful differences in intra-ocular pressure between PF582 and Lucentis at any of the timepoints (Figure 1). Additionally, there were no imbalances in local or systemic adverse events and no unexpected safety or tolerability findings in the population studied.
The efficacy and pharmacodynamic results indicated that there were no meaningful differences in best corrected visual acuity (Figure 2) and the decreases in central retinal thickness (Figure 3) between PF582 and Lucentis at any of the timepoints were also similar.
The immunogenicity results (Figure 4) showed comparable anti-drug antibody findings between PF582 and Lucentis throughout the three month study period.
This first-in-human study met its primary objective of demonstrating similar safety and tolerability between PF582 and Lucentis. Additionally, it demonstrated consistent pharmacological activity between PF582 and Lucentis.
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE
Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug ScreeningNews
A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Structural and Molecular Biology 2018
Aug 22 - Aug 23, 2018
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018